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Key points: 
1) We have developed a technique to measure platelet function and oxidative stress 
simultaneously, which will accelerate research in this field. 
2) We have highlighted common patterns and key differences in redox responses to 
different stimuli, which may open new drug discovery opportunities 
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Abstract 
The regulation of platelets by oxidants is critical for vascular health and may explain 
thrombotic complications in diseases such as diabetes and dementia, but remains 
poorly understood.  
Here, we describe a novel technique combining electron paramagnetic resonance 
spectroscopy and turbidimetry, which has been utilised to monitor simultaneously 
platelet activation and oxygen radical generation. This technique has been used to 
investigate the redox-dependence of human and mouse platelets. 
Using selective peptide inhibitors of NOXs on human platelets and genetically 
modified mouse platelets (NOX1-/- or NOX2-/-), we discovered that:1) intracellular but 
not extracellular superoxide anion generated by NADPH oxidases (NOXs) is critical 
for platelet activation by collagen; 2) superoxide dismutation to hydrogen peroxide is 
required for thrombin-dependent activation; 3) NOX1 is the main source of oxygen 
radicals in response to collagen, while NOX2 is critical for activation by thrombin; 4) 
two platelet modulators, namely oxidised low density lipoproteins (oxLDL) and 
amyloid peptide β (Aβ), require activation of both NOX1 and NOX2 to pre-activate 
platelets.  
This study provides new insights on the redox dependence of platelet activation. It 
suggests the possibility of selectively inhibiting platelet agonists by targeting either 
NOX1 (for collagen) or NOX2 (for thrombin). Selective inhibition of either NOX1 or 
NOX2 impairs the potentiatory effect of tested platelet modulators (oxLDL and Aβ), 
but does not completely abolish platelet haemostatic function. This information offers 
new opportunities for the development of disease specific antiplatelet drugs with 
limited bleeding side effects by selectively targeting one NOX isoenzyme.   
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Introduction 
Platelets are anucleated circulating cells responsible for initiating haemostasis via 
thrombus formation and blood clotting. The regulation of platelets is of primary 
importance for cardiovascular medicine and for the discovery of new drugs to treat 
cardiovascular diseases (1). In addition to canonical signalling pathways depending 
on protein kinase activity (2), platelets are regulated in a redox-dependent manner. 
Several lines of evidence suggest that platelets are modulated by extracellular 
reactive oxygen species (ROS) (3) and that platelet activation is essentially 
dependent on the generation of endogenous ROS (4-6). Therefore, the study of 
platelet regulation and haemostasis is shedding light on the interface between ROS 
biochemistry and cellular physiology. Superoxide anion (O2•−) from exogenous 
sources or endogenously produced by platelets is shown to significantly increase 
platelet aggregation and thrombus formation (7). O2•− has a pre-eminent role in 
biology and pathophysiology, as it serves as a progenitor for formation of hydrogen 
peroxide (H2O2), peroxynitrite (ONOO•−) and hydroxyl radical (HO•), and thereby 
plays a key role in the post-translational oxidative modification of proteins (8). The 
work of several research groups has focussed on NADPH oxidases (NOXs) as 
important sources of ROS in platelets responsible for the regulation of platelet 
responsiveness (9-15). Despite the increased interest on this aspect of platelet 
biology and haemostasis regulation, progress within this field is hampered by the 
lack of reliable and quantitative techniques for the analysis of platelet oxidative state 
(16, 17). This has made it challenging to completely appreciate the importance of 
endogenous and exogenous oxidants on the regulation of platelet signalling 
pathways and on the balance between haemostasis and thrombosis in health and 
disease. Indirectly, this has impeded the development of pharmacological treatments 
for thrombotic conditions based on the control of ROS generation. We addressed 
this biomedical need by combining the measurement of platelet activation (using 
turbidimetry (18)) and the simultaneous measurement of intracellular or extracellular 
oxygen radicals (using electron paramagnetic resonance or EPR spectroscopy (19, 
20)) into one multiplex technique that allows the accurate study of the oxidative state 
and function of human platelets.  
This technique is likely to find application in clinical practice, where the simultaneous 
analysis of platelet responsiveness and oxidative stress can aid developing more 
advanced diagnostics for patients at risk of thrombotic diseases. It could also find 
application in drug discovery, as NOX modulation is becoming an important 
therapeutic strategy in several diseases (21, 22). In the cardiovascular field, in order 
to avoid side effects and bleeding complications of antithrombotic drugs, modern 
drug discovery aims to develop targeted approaches to interfere with the contribution 
of platelets to pathological alterations of the vascular system while preserving their 
vascular protective functions (23, 24). Within this context, it is imperative to deepen 
our understanding of the regulation of platelets in both health and disease, as redox-
dependent regulation of platelets remains poorly understood (25). Our novel 
approach can help to clarify redox-dependent mechanisms regulating platelets and 
haemostasis, validate new drug discovery targets and identify novel antiplatelet drug 
candidates. 
In this study, we utilised the EPR/turbidimetry technique to clarify the dynamics of 
oxygen radical generation and activation in human platelets in response to 
physiological and pathological stimuli. The use of NOX1- and NOX2-selective 
peptide inhibitors allowed for the identification of key differences in the involvement 
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of these two enzymes in the response to platelet agonists and modulators. The 
application of this technique will further our understanding of redox-dependent 
platelet regulation and may have important consequences for antiplatelet drug 
discovery, where the quest for truly pathway-specific inhibitors targeting pathological 
platelet activation without interfering with their physiological haemostatic function 
remains an unmet objective.  
 
Methods 
A detailed description of the methods is available as supplemental material available 
online. 
 
Platelet preparation 
Human blood was drawn from healthy volunteers by median cubital vein 
venepuncture following Royal Devon and Exeter NHS Foundation Trust Code of 
Ethics and Research Conduct and under NRES South West – Central Bristol ethics 
committee approval (Rec n. 14/SW/1089). Sodium citrate was used as anticoagulant 
(0.5% w/v). PRP was separated from whole blood by centrifugation (250 × g, 17 
min), and platelets were separated from PRP by a second centrifugation step (500 × 
g, 10 min), in the presence of prostaglandin E1 (PGE1, 40 ng/ml) and indomethacin 
(10 μM).  
 
EPR/turbidimetry assay 
2×108 platelets/ml were prepared as described above. Prior to adding stimuli, 200 
µM CMH or PPH was added to platelets. Platelet suspensions were loaded onto a 
Chronolog 700-2 aggregometer with continuous stirring and the turbidimetry 
readings were immediately started. 50 μl of platelet-free supernatant were 
transferred into the Hirschmann precision micropipettes and read using an e-scan 
(Noxygen, Germany).  
 
Thrombus formation under physiological flow assay 
The Bioflux200 system (Fluxion, South San Francisco, CA) was used to analyse 
thrombus formation in human and mouse whole blood under flow. Heparin-
anticoagulated whole blood was incubated with scrambled or the NOX inhibitory 
peptides, NoxA1ds and Nox2ds-tat before the addition of 1 μM DiOC6 for 10 minutes 
before the blood was added to the wells. Thrombus formation was visualized by 
fluorescence microscopy at a shear rate of 1000 sec−1 
 
Results 
Superoxide anion-dependence of platelet activation by collagen but not 
thrombin 
Generation of ROS in a living cell can be examined by electron paramagnetic 
resonance (EPR) spectroscopy using 1-hydroxy-3-methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine (CMH), an oxygen radical-specific spin probe (16). This spin 
probe crosses the plasma membrane and directly reacts with intracellular oxygen 
radicals to generate a nitroxide adduct that can be detected by EPR spectroscopy 
(Supplementary Figure 1A-B). We combined classical aggregometry (also known as 
turbidimetry) with CMH-dependent and EPR spectroscopy by analysing CMH 
oxidation in the platelet supernatant while the aggregation reaction is taking place 
(Supplementary Figure 1C).  EPR is considered a gold standard for ROS detection 
and offers the important advantage of providing a quantification of the generation 
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rate of oxygen radicals. As shown in Supplementary Figure 2A-B, it is in fact possible 
to build a calibration curve using known concentrations of the nitroxide adduct (CM●). 
Knowing platelet suspension density and incubation time, it is therefore possible to 
interpolate experimental data of resonance intensity into CMH oxidation rates (moles 
per platelet per minute, using the formula shown in Supplementary Figure 2C). This 
assay allowed us to correlate platelet aggregation induced by collagen and thrombin 
with the rate of oxygen radical generation (measured as rate of CMH oxidation). 
Collagen was tested at concentrations ranging from 1 to 30 µg/ml and both 
aggregation kinetics (Figure 1A) and oxygen radical generation rates at 10 minutes 
from stimulus delivery (Figure 1B) were concentration-dependent. Similarly to 
collagen, a synthetic collagen-related peptide (CRP) that selectively engages GPVI 
receptor (but not other collagen-binding receptors on platelets), also led to 
concentration-dependent O2•− formation that was necessary for platelet aggregation 
(Supplementary Figure 3). Thrombin also showed concentration-dependence of both 
EPR and aggregation responses between 0.03 and 1 unit/ml (Figure 1C and D, 
respectively). Supplementary Table 1 shows the EC50 values of these three 
agonists for EPR detection of superoxide anion generation and aggregation 
response.  
In order to confirm the chemical nature of the oxygen radicals generated by platelets 
upon activation and detected by EPR, we utilised cell-permeant pegylated 
superoxide dismutase (PEG-SOD), which scavenges O2•− by dismuting it into H202. 
The EPR signal detected in human platelets stimulated by collagen and thrombin 
was abolished by PEG-SOD, suggesting that O2•− is the oxygen radical species 
generated under these conditions (Supplementary Figure 4A and C, respectively). 
The generation of O2•− radicals appeared necessary for platelet activation by 
collagen, as the scavenging of this oxygen radical by PEG-SOD significantly 
inhibited aggregation in response to this agonist (Supplementary Figure 4B). On the 
other hand, thrombin-dependent aggregation was not affected by PEG-SOD, 
suggesting that O2•− is not an essential component of the signalling cascades 
induced by this agonist. Similarly to collagen, both EPR and aggregation signals in 
response to CRP were abolished by PEG-SOD (Supplementary Figure 3C and D). 
The data obtained with PEG-SOD were confirmed using another O2•− scavenger, 4-
hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (or TEMPOL). In Supplementary Figure 
5, we show that TEMPOL abolishes the EPR signal in response to either collagen or 
thrombin (Supplementary Figure 5A and B, respectively), whilst only the aggregation 
response to collagen but not thrombin (Supplementary Figure 5C and D, 
respectively) is inhibited. Interestingly, the non-selective antioxidant and cell 
permeable amino acid N-acetyl cysteine (NAC) inhibits aggregation induced by both 
collagen and  thrombin, suggesting that the thrombin responses depend on oxidative 
reactions, but that O2•−, per se, is not the oxidant species involved in this response 
(Supplementary Figure 5C and D). In order to confirm that the CMH-based EPR did 
not detect H202 (another major ROS) in our hands, we performed experiments in the 
presence of catalase (CAT, non-cell permeable) and pegylated catalase (PEG-CAT, 
cell permeable), which convert H202 to water (Supplementary Figure 6). No effect of 
either enzymes on the collagen- or thrombin-induced EPR signal was observed, 
proving the specificity of the CMH-based EPR measurements for oxygen radicals 
and O2•− in particular.  
 
Low levels of superoxide anion are released by platelets although they are not 
required for platelet activation. 
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We demonstrated that the CMH-based EPR spectroscopy predominantly measures 
intracellular but not extracellular platelet O2•− in response to either collagen or 
thrombin (Supplementary Figure 7), as the non-pegylated and thus non-cell 
permeable version of the enzyme superoxide dismutase (SOD) did not affect the 
responses. Interestingly, we also utilised a non-cell permeable EPR probe called 1-
Hydroxy-4-phosphono-oxy-2,2,6,6-tetramethylpiperidine (or PPH) to detect 
extracellular O2•− released by platelets (Supplementary Figure 8A-D). Noticeably, the 
scavenging of extracellular O2•− with SOD was effective in abolishing the PPH-based 
signal (Supplementary Figure 8E-F), but did not affect collagen- or thrombin-induced 
aggregation (Supplementary Figure 8G-H), suggesting that extracellular O2- does 
not participate in the process of platelet activation. In addition, we confirmed the 
formation of H202 in response to collagen or thrombin using the H2O2-specific probe 
Amplex Red (Supplementary Figure 9 A-B) and that catalase effectively quenched 
the signal. More importantly, the degradation of H202 by catalase or pegylated 
catalase inhibited platelet aggregation stimulated by thrombin, but not collagen 
(Supplementary Figure 9 C-F). This suggests that H202 is a critical component of the 
signalling triggered by thrombin but not collagen.   
 
Differential role of NADPH oxidases 1 and 2 in collagen- and thrombin-
dependent activation of human platelets 
We utilised the combinatorial EPR/aggregometry that we developed to assess the 
role of NOX1 and NOX2 in platelet activation by collagen and thrombin. In 
experiments illustrated in Figure 5, we used the NOX1-specific inhibitory peptide 
NoxA1ds to assess the role of this enzyme in platelet activation (26). NOX1 inhibition 
almost completely inhibited oxygen radical formation in response to collagen (Figure 
2A), but not thrombin (Figure 2C). In parallel, collagen- (Figure 2B) but not thrombin-
dependent (Figure 2D) aggregation was inhibited by NoxA1ds. Importantly a 
scrambled version of the peptide was used as control. Taken together, these data 
suggest that NOX1 is activated and participates in the signalling of platelet activation 
in response to collagen but not thrombin. We also tested the role of NOX2 using the 
specific inhibitory peptide Nox2ds-tat (27, 28). In Figure 3, we show that both 
collagen- and thrombin-dependent oxygen radical formation are significantly 
impaired by NOX2 inhibition (Figure 3A and C, respectively). Interestingly, although 
the inhibition of the thrombin response by Nox2ds-tat reduces oxygen radical 
formation to basal levels, the inhibition of collagen-induced oxygen radical levels is 
only partial (i.e. in the presence of Nox2ds-tat the oxygen radical levels induced by 
collagen are significantly higher than resting controls). This is reflected in the 
aggregation data, which show complete inhibition by Nox2ds-tat of the aggregation 
induced by thrombin but only marginal inhibition of the response to collagen (Figure 
3D and B, respectively). This is consistent with NOX1 playing a larger role than 
NOX2 in collagen-induced platelet aggregation. The data obtained with collagen 
were essentially confirmed using the synthetic ligand for GPVI CRP (Supplementary 
Figure 10), which suggests that GPVI is the key receptor linking collagen-dependent 
platelet activation to oxygen radical generation and determines the redox patterns 
triggered by collagen in platelets. The active engagement of NOX1 and NOX2 in 
collagen and thrombin signalling was confirmed by co-immunoprecipitation of these 
two core subunits with respective essential cytosolic components of each complex. 
As shown in Figure 4A, NOX1 is co-immunoprecipitated with its canonical activating 
subunit NOXA1 (29) in the presence of collagen, which is consistent with NOX1 
being post-translationally activated in response to collagen. In Figure 4C, NOX2 
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appears to be co-immunoprecipitated with its canonical organizing subunit p47phox 
in the presence of thrombin and weakly in the presence of collagen. This aligns with 
the conclusions reached using our EPR and aggregation experiments, i.e. that 
collagen activates a primarily NOX1-dependent response, while thrombin activates 
primarily NOX2. Accordingly, whole blood thrombus formation experiments on 
collagen showed that NOX1 inhibition with NoxA1ds abolishes thrombus formation 
(Figure 4B), while NOX2 inhibition by Nox2ds-tat induces only a marginal inhibition 
(Figure 4D). Experiments in platelets from wild type, NOX1-/- or NOX2-/- mice 
confirmed the centrality of NOX1 for collagen signalling with marginal involvement of 
NOX2 in the aggregation response (Figure 5A and B), while NOX2 is critical for 
thrombin signalling (Figure 5C).     
 
Role of NOX1 and NOX2 in mediating the effect on platelets of weak 
agonists/positive modulators oxidised LDL (oxLDL) and amyloid beta (Aβ1-42). 
Employing these tools (NoxA1ds (26) and Nox2ds-tat (27, 28)), we determined that 
NOX1 or NOX2 play an equivalent role in the generation of superoxide anion in 
response to oxLDL (Figure 6A) and that both enzymes are required for the 
stimulation of the modest aggregation induced by this modulator (Figure 6B). As 
suggested by the inhibition of aggregation by PEG-SOD, O2•− is the oxidant 
molecule required for the activation of platelets by oxLDL. It is important to note how 
oxLDL elicits a very modest aggregation (both as size and kinetic of the response), 
which conforms to the designation of oxLDL as a modulator rather than agonist (i.e. 
exerting its effect by enhancing the responsiveness of platelets to low agonist 
levels). In fact, low concentrations of collagen (Figure 6C) or thrombin (Figure 6D) 
characterised by the ability to induce no/low aggregation, resulted able to induced a 
robust platelet aggregation in the presence of ox-LDL. The synergistic effect of 
oxLDL in combination with thrombin or collagen was inhibited by NoxA1ds (Figure 
6C) or Nox2ds-tat (Figure 6D), respectively. We could not test NoxA1ds on ox-LDL + 
collagen or Nox2ds-tat on oxLDL + thrombin, because as shown above NoxA1ds 
inhibits collagen directly and Nox2ds-tat inhibits thrombin directly.  Similarly, Aβ1-42 
induces O2•− formation via activation of NOX1 and NOX2 (Figure 7A), which leads to 
a modest platelet aggregation (Figure 7B). On the other hand, similarly to oxLDL, 
Aβ1-42 displays the ability to synergistically increase the aggregation response to 
low concentrations of collagen (Figure 7C) or thrombin (Figure 7D). As proved with 
inhibitory peptides NoxA1ds (26) and Nox2ds-tat (27, 28), the synergistic effect on 
collagen- or thrombin-induced aggregation is NOX1- or NOX2-dependent, 
respectively. We could not test NoxA1ds on Aβ1-42 + collagen or Nox2ds-tat on 
Aβ1-42 + thrombin, because as shown above NoxA1ds inhibits collagen directly and 
Nox2ds-tat inhibits thrombin directly. Transgenic mice NOX1-/- and NOX2-/- were 
utilised to assess the NOX-dependence of the responses to oxLDL and Aβ1-42. As 
ox-LDL coating of surfaces is not commonly used and there is not accepted protocol 
for it, we tested the effect of oxLDL added to mouse blood on thrombus formation on 
low levels (i.e. 0.05 mg/ml) of collagen coating (Figure 8A). These data showed that 
oxLDL potentiates the thrombus formation on collagen in a NOX2-dependent 
manner (as it was not evident in NOX2-/- blood). NOX1 ablation inhibits collagen 
responses directly, therefore we could not investigate the role of NOX1 in the 
potentiation of responses to this agonists by oxLDL. The ablation of either NOX1 or 
NOX2 silencing significantly also impairs thrombus formation at physiological arterial 
shear on absorbed Aβ1-42 (1,000 sec-1) (Figure 8C), At low shear (200 sec-1), 
mouse platelets display low levels of adhesion to absorbed Aβ1-42 without formation 
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of thrombi, which was inhibited by NOX1 genetic silencing but unaffected by NOX2 
ablation (Supplementary Figure 11). As these modulators induce little or no 
aggregation on their own, we analysed the modulatory effect of oxLDL and Aβ1-42 in 
aggregation experiments using NOX1-/- and NOX2-/- mouse platelets. We showed 
that oxLDL (Figure 8B) and Aβ1-42 (Figure 8D) potentiate the aggregation induced 
by collagen in wild type mice but not in NOX2-/- mice, and the aggregation stimulated 
by thrombin in wild type mice but not in NOX1-/- mice. The potentiation of collagen 
response could not be tested in NOX1-/- mice, which do not respond to this stimulus, 
while the potentiation of thrombin responses could not be tested in NOX2-/-, for the 
same reason.  
 
Discussion 
The study of platelet function is critical to understanding vascular homeostasis and 
disease. A thorough understanding of the redox-dependent regulation of platelet 
function has been hampered by the lack of a reliable technique to measure 
intracellular ROS (16, 17). We have resolved this problem by optimising an EPR-
based technique for the detection of oxygen radical and combining it with a classical 
turbidimetric assay for the simultaneous measurement of platelet aggregation. 
Although EPR has been used for the analysis of ROS formation in live cells 
previously (16, 17), this technique has never been applied to the study of platelet 
redox signalling. We utilised the assay developed here to clarify several unknown 
aspects of the regulation of platelet activity by endogenous oxidants.  
The molecular mechanisms underlying the redox dependence of platelet activation in 
response to collagen, thrombin, and oxidised LDL are summarised in Supplementary 
Figure 12. Although, the dependence of platelet activation on the generation of 
endogenous ROS has been described (1-6), here for the first time we elucidated the 
chemical nature of the ROS involved in the signalling of different platelet agonists 
and modulators. O2•− are generated in response to all tested agonists and 
modulators, but although these ROS are directly involved in the signalling of 
collagen, ox LDL and Aβ1-42, their dismutation to hydrogen peroxide is necessary 
for the signalling of thrombin. The literature on this aspect of platelet biology is quite 
inconclusive because of the use of different techniques and conditions. Although 
previous studies reported the generation of hydrogen peroxide in response to 
thrombin (and leading to apoptosis) (30), this study for the first time highlights a 
significant difference in the role of hydrogen peroxide in the responses to collagen 
and thrombin. Our observations on the link between thrombin-dependent activation 
and hydrogen peroxide contradict previous reports pointing to a role for hydrogen 
peroxide in collagen but not thrombin signalling (31). The experimental differences in 
our and previous studies are extensive and the poor specificity of the tools used for 
older studies (e.g. 2',7'–dichlorofluorescein diacetate or DCFDA) are potentially 
responsible for these discrepancies.  
Another important addition to our understanding of redox regulation of platelets is the 
clarification of whether oxidants act intracellularly or extracellularly. Our data clearly 
suggest that platelet O2•− acts intracellularly in these responses, as only cell 
permeable scavenger can affect their activity (i.e. PEG-SOD), while hydrogen 
peroxide is likely to be formed by dismutation of intracellular O2•− and released 
extracellularly, where it potentiates platelet responses induced by thrombin (as 
proved by the effect of non-cell permeable catalase shown in supplementary Figure 
6).  These findings add significantly to our understanding of platelet redox regulation 
and are in agreement with previous suggestion of an intracellular function for O2•− 
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(32, 33). It is also in agreement with the observation of a positive regulatory role for 
extracellular hydrogen peroxide in thrombin-induced responses (34) and a role for 
extracellular oxidants in the regulation of platelet surface receptor function by protein 
disulphide isomerases (PDIs) (35).  Regarding the redox-dependence of the collagen 
signalling in platelets, although further studies are required, protein tyrosine 
phosphatases (PTPs) are the most likely link between redox and conventional 
signalling in platelets (36). The oxidative inactivation of protein phosphatases has in 
fact been suggested to play a key role in the activation and regulation of the 
pathophysiological roles of platelets (37). The Src Homology Phosphatase 2 (SHP2) 
has been shown to play an important role as a negative regulator of platelet 
activation (38) and recent studies demonstrated that ROS generated during platelet 
activation oxidise and inhibit SHP2. This, in turns, facilitates the activation of protein 
kinase-mediated signalling pathways and drives the processes associated with cell 
activation (e.g. adhesion receptor activation, shape change, etc.)  (37, 39). 
In this study, we also highlight the differential involvement of NOX1 and NOX2 in 
physiological agonist signalling (i.e. collagen and thrombin). NOX1 is essential for 
the signalling of collagen with NOX2 inhibition only partially reducing collagen-
dependent aggregation and O2•− formation, in both human (Figure 3A-B) and mouse 
(Figure 5A) platelets. The secondary role of NOX2 in collagen responses is further 
demonstrated by thrombus formation experiments under physiological flow, which is 
marginally but significantly reduced by NOX2 inhibition/silencing in human but not 
mouse blood (i.e. Figure 4D vs Figure 5B). This discrepancy between thrombus 
formation in human and mouse blood could be suggestive of a higher involvement of 
NOX2 in collagen responses of human platelets. In any case, the dominant role of 
NOX1 in collagen response is clear in our experiments both in human and mouse 
platelets. Similarly, NOX2 is essential for the signalling of thrombin without NOX1 
involvement in human platelets (Figure 2C-D) and limited yet significant involvement 
in mouse platelets (Figure 5C). This is in agreement with previous indications from 
our and other groups (14, 40), but in essential disagreement with a recent study in 
mouse platelets reaching opposite conclusions (i.e. NOX1 involvement in thrombin 
signalling and NOX2 involvement in Collagen signalling) (13). Some differences can 
be expected between signalling pathways and redox dependence of human and 
mouse platelets, which may explain this discrepancy. Overall, combining human and 
mouse platelet data, it is safe to state that thrombin-dependent aggregation depends 
very heavily on NOX2 activity (although a role of NOX1 in thrombin was detected in 
mouse platelets, which we did not observe in human platelets), while collagen-
induced aggregation was predominantly NOX1-dependent with marginal involvement 
of NOX2 (as shown in our human platelet data). So, although mouse platelets 
display some engagement of NOX1 in thrombin responses, species-specific 
differences cannot fully explain the discrepancy between our report and Delaney’s 
work. The fact that Delaney and colleagues used male animals for NOX1 studies 
and females for NOX2 studies may explain some of the differences with our study 
(performed entirely on female animals). Other potentially important differences are in 
the platelet isolation procedure, the concentration of agonists (very low concentration 
of thrombin used) and the use of collagen-related peptide instead of collagen.    
In addition to physiological stimuli, in this study we analysed the effect of oxidised 
LDL and Aβ1-42, platelet modulators associated with the thrombotic complications of 
atherosclerosis (41) and cerebrovascular amyloid angiopathy (CAA) (42), 
respectively. Both oxidised LDL and Aβ1-42 have been shown to activate platelets 
and act as positive modulators (15, 43). We confirmed the ability of these molecules 
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to induce partial platelet aggregation. On the other hand, they were able to 
significantly increase the responses to low levels of physiological agonists. This 
mode of action is consistent with the definition of positive modulators or primers (44), 
which are characterised by the ability to trigger an unwanted haemostatic response 
and clot formation leading to thrombosis. The involvement of platelet positive 
modulators in thrombotic complications associated with diseases is particularly 
important for vascular health and relative pharmacotherapy (45). Interestingly, the 
aggregation induced by these primers was also redox-dependent and inhibited by 
the O2•− scavenger PEG-SOD. This is in agreement with previous literature on 
oxLDL (15, 46) and Aβ1-42 (47), and supports the hypothesis that platelet primers 
may act in a redox-dependent manner (48).  
Also intriguing were our conclusions regarding the involvement of NOX1 and NOX2 
in the signalling of oxLDL and Aβ1-42. We provide compelling evidence in human 
platelets with NOX-selective inhibitors Nox2ds-tat and NoxA1ds or in genetically 
modified mouse platelets (NOX1-/- or NOX2-/-) that both NOX1 and NOX2 are 
activated by oxLDL and Aβ1-42 and they are both required for the functional effects 
of these pathology-associated modulators on platelets. These conclusions were 
confirmed by experiments with transgenic mouse platelets, both in thrombus 
adhesion and aggregation experiments. Only adhesion to Aβ1-42 under low shear 
seemed exclusively NOX1-dependent. This is a low level adhesion response 
incapable of properly triggering thrombus formation (Supplementary Figure 11). 
These data may therefore suggest a differential involvement of NOX1 and NOX2 in 
different molecular events triggered by Aβ1-42. This hypothesis would deserve 
further study for satisfactory elucidation. The involvement of NOX2 in the signalling 
of oxLDL has been suggested previously (15, 46), while the involvement of NOX1 is 
novel. The possibility of abolishing the effect of oxLDL and Aβ1-42 on platelets by 
inhibiting only one of the two NOXs may suggest that both enzymes are required for 
reaching a threshold in the superoxide anion levels leading to platelets stimulation. 
The similarities between the activity and redox-dependence of oxLDL and Aβ1-42 
may suggest that they act on similar receptors. As suggested by literature for both 
molecules, the receptors that these platelet modulators are likely to be CD36 (15, 
49). Importantly, the fact that both platelet NOXs are required for the modulatory 
activity of oxLDL or Aβ1-42 offers the opportunity of targeted intervention without the 
complete inhibition of the response to physiological agonists. In other words, the 
inhibition of only one NOX isozyme could reduce the pro-thrombotic tendencies 
associated with vascular inflammation without completely impairing the haemostatic 
response (i.e. NOX1 inhibition will not impair thrombin response, while NOX2 
inhibition will not impair collagen responses). This is the ultimate goal of modern 
antiplatelet drug discovery and may help to resolve the persisting problem of 
bleeding risks associated with all existing antiplatelet treatment (50).  
In summary, herein we describe the development and application of a novel 
approach to simultaneously monitor the generation of oxygen radicals and platelet 
aggregation. This technique has the potential to become a standard technique to 
assess platelet responsiveness and thrombotic risks associated to vascular 
conditions in a clinical setting. In addition, this study allowed the identification of 
patterns of platelet regulation and the clarification of the mode of action of 
physiological agonists and pathological modulators of platelets. The results of this 
study also highlight the potential of NADPH oxidase targeting for the development of 
novel antiplatelet drugs with better pharmacodynamic profiles (i.e. limited bleeding 
side effects). 
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Figure legends 
 
Figure 1: Oxygen radical generation by platelets activated by physiological 
stimuli collagen and thrombin. Washed human platelets were prepared as 
described. Collagen was tested at concentrations ranging from 1 to 30 µg/ml, while 
thrombin from 0.03 to 1 unit/ml. EPR was used to measure oxygen radicals 
formation as CMH oxidation rates (32.7 and 37.3 attomoles per platelet per minute, 
respectively) (A and C) and aggregation was simultaneous assessed by turbidimetry 
(B and D). For either technique, representative examples are shown in top panels, 
while quantification is shown in the bottom panels.  Aggregation curves up to 5 
minutes are shown, while EPR resonance readings were taken after 10 minutes of 
stimulation. Examples of EPR traces and aggregation curves are representative of 4 
independent experiments. Statistical analysis was performed by one-way ANOVA 
with Bonferroni post-hoc test (* = p <0.05, compared to resting platelets, n=4 for A-
D). 
 
 
 
 
Figure 2: NOX1 is specifically involved in platelet activation by collagen but 
not thrombin. CMH was utilised for the detection of oxygen radicals generated by 
platelets. 10 µg/ml collagen (A) or 0.1 unit/ml thrombin (C) were tested. 10 µM of 
NoxA1ds abolished the EPR response measured in the presence of collagen. The 
scrambled peptide at the same concentration (scNoxA1ds) was used as a negative 
control. Interestingly, the inhibition of NOX1 by NoxA1ds also inhibited collagen- (B), 
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but not thrombin-dependent (D) platelet aggregation. Aggregation curves for up to 5 
minutes are shown, while EPR resonance readings were taken after 10 minutes of 
stimulation. Examples of EPR traces and aggregation curves are representative of 3 
or more independent experiments. Statistical analysis was performed by one-way 
ANOVA with Bonferroni post-hoc test for EPR (* = p <0.05, compared to resting 
platelets) or t test for aggregation (* = p <0.05, compared to scrambled control, n=3 
for A-D). 
 
Figure 3: NOX2 is activated by both collagen and thrombin, but essential only 
for platelet aggregation induced by thrombin. CMH was utilised for the detection 
of oxygen radicals generated by platelets. 10 µg/ml collagen (A) or 0.1 unit/ml 
thrombin (C) were tested. 10 µM of Nox2ds-tat inhibited the EPR response 
measured in the presence of either collagen or thrombin, although the collagen-
dependent response remained significantly higher than resting levels of oxygen 
radical formation. The scrambled peptide at the same concentration (scNox2ds-tat) 
was used as a negative control. Interestingly, the inhibition of NOX2 by Nox2ds-tat 
also inhibited thrombin- (D), but not collagen-dependent (B) platelet aggregation. 
Examples of EPR traces and aggregation curves are representative of 3 or more 
independent experiments. Statistical analysis was performed by one-way ANOVA 
with Bonferroni post-hoc test for EPR (* = p <0.05, compared to resting platelets) or t 
test for aggregation (* = p <0.05, compared to scrambled control) n=4 for C and D, 
n=5 for A and n=7 for B). 
 
Figure 4: NOX1 is the main source of superoxide anions in human platelet 
response to collagen, while NOX2 is the main source of thrombin-dependent 
ROS. The activation of NOX1 (A) and NOX2 (B) was assessed by co-
immunoprecipitation with their canonical activating and organising subunits NOXA1 
and p47phox, respectively. 400 µl of platelet suspension (4 x 108 platelets/ml) were 
stimulated with 10 µg/ml collagen or 0.1 unit/ml thrombin or vehicle solution 
(Tyrode’s buffer) for 10 minutes before gentle cell lysis (NP40 buffer). Specific NOX1 
or NOX2 antibodies and Protein A/G were used to immunoprecipitate the NOX 
complexes (which by extension should include their regulatory subunits after 
activation). The immunoprecipitates were tested by immunoblotting using NOX1, 
NOXA1, NOX2 or p47phox antibodies (as indicated). The data are representative of 
4 independent experiments. The functional role of NOX1 and NOX2 in collagen-
dependent platelet activation was assessed in a whole blood flow assay (C and D). 
Platelets were stained with DiOC6 as described and the Bioflux platform (Fluxion, 
San Francisco) was utilised to assess the thrombus formation induced by collagen 
under physiological flow (1000 sec-1). The experiments were performed in the 
presence of NoxA1ds or its negative scrambled control (C) or Nox2ds-tat or its 
negative scrambled control (D). Images were taken at 10 minutes of flow and are 
representative of 4 independent experiments. They were quantified by assessing the 
surface area coverage by platelets (lower section of panels C and D). Statistical 
significance was tested by t test (* = p <0.05, compared to scrambled control, n=4 for 
B and D).    
 
Figure 5. NOX1- and NOX2-dependence of collagen and thrombin aggregation 
and superoxide generation tested in transgenic mice. Platelets were isolated for 
wild type (C57BL6/J), NOX1-/- or NOX2-/- mice exsanguinated via intracardiac 
puncture and resuspended at 2×108 platelets/ml density. Platelets were stimulated 
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with 3 µg/ml collagen (A) or 0.1 unit/ml thrombin (C). Aggregation (left panels) and 
superoxide anion formation (right panels) were measured as described for 5 and 10 
minutes respectively. (B) The functional role of NOX1 and NOX2 in collagen-
dependent platelet activation was also assessed in a whole blood flow assay. 
Platelets were stained with DiOC6 and the Bioflux platform (Fluxion, San Francisco) 
was utilised to assess the thrombus formation induced by collagen under 
physiological flow (1,000 sec-1). Images were taken at 10 minutes of flow and are 
representative of 4 independent experiments. They were quantified by assessing the 
surface area coverage by platelets with Image J. Data are representative of 4 
independent experiments. Statistical analysis was performed by one-way ANOVA 
with Bonferroni post-hoc test (* = p <0.05, n=4 for A-C). 
 
Figure 6: NOX1 and NOX2 are required for the induction of superoxide anion 
formation and platelets activation by oxidised LDL. Oxygen radical generation 
(A) and platelet aggregation (B) in response to oxLDL were measured as described. 
10µM of scrambled NoxA1ds (scNoxA1ds), NoxA1ds, scrambled Nox2ds-tat 
(scNox2ds-tat), Nox2ds-tat or 100 unit/ml of PEG-SOD were pre-incubated 10 
minutes before platelet stimulation with  50 ng/ml oxidised LDL (oxLDL). Examples of 
EPR traces and aggregation curves are representative of 4 independent 
experiments. Statistical analysis was performed by one-way ANOVA with Bonferroni 
post-hoc test (* = p <0.05, n=3 for B and n=4 for A). The effect of oxLDL as platelet 
modulator was investigated by traditional aggregometry (C and D). Pre-incubation 
with 50 ng/ml oxLDL for 10 minutes was followed by stimulation with 3µg/ml collagen 
(C) or 0.03 unit/ml thrombin (D). In order to test the dependence of the modulatory 
effect of oxLDL on NOX1 and NOX2, 10 µM scrambled NoxA1ds (scNoxA1ds), 
NoxA1ds, scrambled Nox2ds-tat (scNox2ds-tat), Nox2ds-tat were pre-incubated (10 
minutes before addition of oxLDL). Aggregation curves are representative of 4 
independent experiments.  
 
Figure 7: NOX1 and NOX2 are required for the induction of superoxide anion 
formation and platelets activation by amyloid peptide β 1-42. Oxygen radical 
generation (A) and platelet aggregation (B) in response to amyloid peptide β 1-42 
(Aβ1-42) were measured as described. 10µM of scrambled NoxA1ds (scNoxA1ds), 
NoxA1ds, scrambled Nox2ds-tat (scNox2ds-tat), Nox2ds-tat or 100 unit/ml of PEG-
SOD were pre-incubated 10 minutes before platelet stimulation with  20µM Aβ1-42. 
Examples of EPR traces and aggregation curves are representative of 4 
independent experiments. Statistical analysis was performed by one-way ANOVA 
with Bonferroni post-hoc test (* = p <0.05, n=3 for A and B). The effect of Aβ1-42 as 
platelet modulator was investigated by traditional aggregometry (C and D). Pre-
incubation with 20µM Aβ1-42 for 10 minutes was followed by stimulation with 3µg/ml 
collagen (C) or 0.03 unit/ml thrombin (D). In order to test the dependence of the 
modulatory effect of Aβ1-42 on NOX1 and NOX2, 10 µM scrambled NoxA1ds 
(scNoxA1ds), NoxA1ds, scrambled Nox2ds-tat (scNox2ds-tat), Nox2ds-tat were pre-
incubated (10 minutes before addition of Aβ1-42). Aggregation curves are 
representative of 4 independent experiments. 
 
Figure 8: Experiments on transgenic mice suggest that NOX1 and NOX2 are 
required for the effect of amyloid peptide β 1-42 and oxidised LDL. Platelets 
from wild type, NOX1-/- or NOX2-/- mice were stained with DiOC6 and the Bioflux 
platform (Fluxion, San Francisco) was utilised to assess the thrombus formation 
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induced by collagen under physiological flow. In A, Ibidi Vena8+ flow chambers were 
coated with 0.05mg/ml collagen and whole blood was treated with 50 ng/ml native 
LDL (nLDL) or oxidised LDL (oxLDL). In C, Ibidi Vena8+ flow chambers were coated 
with 20µM Aβ1-42 or scrambled control peptide (ScAβ1-42). The shear rate utilised 
was either 1,000 sec-1, which leads to thrombus formation. Images were taken at 10 
minutes of flow and are representative of 4 independent experiments. They were 
quantified by assessing the surface area coverage by platelets with Image J. Data 
are representative of 4 independent experiments. Statistical analysis was performed 
by one-way ANOVA with Bonferroni post-hoc test (* = p <0.05, n=4 for A and C). 
Aggregation experiments were performed by pre-treating platelets with 50 ng/ml 
native LDL (nLDL) or oxidised LDL (oxLDL) (B) or 20µM Aβ1-42 or scrambled control 
peptide (ScAβ1-42) (D) for 10 minutes. Low level aggregation was then stimulated 
with either 10µg/ml collagen or 0.03 unit/ml thrombin, as indicated. Aggregation data 
are representative of 3 independent experiments. 
 
 








Online supplement 
Supplemental Methods Section 
Chemicals and reagents 
Cyclic hydroxylamines 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine 
(CMH) and 1-hydroxy-4-phosphono-oxy-2,2,6,6-tetramethylpiperidine (PPH) were 
purchased from Noxygen (Elzach, Germany). Prostaglandin E1 (PGE1), 
indomethacin, superoxide dismutase (SOD), polyethylene glycol-conjugated 
superoxide dismutase (PEG-SOD), catalase (CAT), polyethylene glycol-conjugated 
catalase (PEG-CAT), N-acetylcysteine, 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl 
(or TEMPOL), heparin and thrombin were obtained from Sigma-Aldrich (Poole, UK). 
Stock solutions of cyclic hydroxylamines (10 mM) were prepared in EPR grade 
Tyrode's-HEPES buffer (THB) containing 25 µM deferoxamine methanesulfonate salt 
(DF) and 5 µM sodium diethyldithiocarbamate trihydrate (DETC) purchased from 
Noxygen, (Elzach, Germany). Stock solutions were kept under argon on ice to keep 
an oxygen free atmosphere and were prepared daily. Native LDL (nLDL) and oxidised 
LDL (oxLDL) were purchased from BioRad (Oxford, UK). Horm collagen was from 
Nycomed (Linz, Austria). The NOX inhibitory peptides were obtained from Prof J 
Pagano: Nox2ds-tat (YGRKKRRQRRRCSTRIRRQL), scNox2ds-tat 
(RKKRRQRRRCLRITRQSR), NoxA1ds (EPVDALGKAKV) and scNoxA1ds 
(LVKGPDAEKVA). 
 
Platelet preparation 
Human blood was drawn from healthy volunteers by median cubital vein venepuncture 
under local ethics committee approval. Sodium citrate was used as anticoagulant 
(0.5% w/v). PRP was separated from whole blood by centrifugation (250 × g, 17 min), 
and platelets were separated from PRP by a second centrifugation step (500 × g, 10 
min), in the presence of prostaglandin E1 (PGE1, 40 ng/ml) and indomethacin (10 
µM). Washed platelets were then resuspended in a modified THB with a pH 7.4 (10 
mM HEPES, 145 mM NaCl, 2.9 mM KCl, 1 mM MgCl2, 5 mM glucose, in ESR grade 
water (NOX-07, Noxygen, Germany) at a density of 2 × 108/ml. 
 
EPR/turbidimetry assay 
2×108 platelets/ml were prepared as described in the supplemental methods section. 
Prior to adding stimuli, 200 µM CMH or PPH was added to platelets. Platelet 
suspensions were loaded onto a Chronolog 700-2 aggregometer with continuous 
stirring (1,200rpm at 37°C) and the turbidimetry readings were immediately started. 
After 1 minute, stimuli were delivered and aggregation was measured for 10 minutes. 
After 10 min of aggregation (as determined to optimise the signal-to-noise and 
reproducibility of the assay), 50 µl of platelet-free supernatant were transferred into 
the Hirschmann precision micropipettes and read using an e-scan (Noxygen, 
Germany). EPR spectra were recorded using the following EPR settings: field sweep, 
80 G; microwave frequency, 9.39 GHz; microwave power, 2 mW; modulation 
amplitude, 5 G; conversion time, 327.68 ms; time constant, 5242.88 ms; 512 points 
resolution and receiver gain, 1 × 104. Samples for calibration curves was obtained 
from a 10 mM stock solution of a standard CM● solved in THB, and diluted to 
concentrations of typically 0, 0.3, 1, 3, 10, and 30 µM. Exactly 50 µL of the calibration 
samples was transferred to Hirschmann precision micropipettes. EPR signal from 
samples was utilised to calculate CMH oxidation rate as described in Figure 2. The 
aggregation shown in the figures span for only 5 minutes, which is sufficient for a 
plateau to be reached and differences in the aggregation responses to be evident. 
Aggregation was quantified as % absorbance decrease = (initial absorbance – final 
absorbance) / initial absorbance. EPR was quantified as CMH oxidation, which was 
obtained using a calibration curve for known concentrations of oxidised CMH (CM•) 
(Supplementary Figure 2B) and the formula below: 
 
 
 
 
 
 
Thrombus formation under physiological flow assay 
The Bioflux200 system (Fluxion, South San Francisco, CA) was used to analyse 
thrombus formation in human and mouse whole blood under flow. Microchannels were 
coated with 0.1/0.05 mg·mL−1 collagen I (monomeric collagen from calf skin, Sigma, 
UK) for 1–2 hours at 37°C before blocking with 1% BSA in Tyrode’s-HEPES buffer 
and washing with Tyrode’s-HEPES buffer. Heparin-anticoagulated whole blood was 
incubated with scrambled or the NOX inhibitory peptides, NoxA1ds and Nox2ds-tat 
before the addition of 1 µM DiOC6 for 10 minutes before the blood was added to the 
wells. Thrombus formation was visualized by fluorescence microscopy at a shear rate 
of 200 or 1,000 sec−1. Representative pictures were taken at 10 min and surface area 
coverage was determined using Image J.  
 
Immunoprecipitation and pull-down assay 
After stimulation, platelet were lysed under milder condition using a gentle lysis buffer 
(Tris 50 mM, NaCl 200 mM, Nonidet P-40 1%, Na deoxycholate 0.5%, and pH 7.4) 
with protease and phosphatase inhibitors. NOX1 or NOX2 was immunoprecipitated 
with 1 µg of rabbit mAb (Novus and Abcam respectively) overnight at 4 °C and the 
immunocomplexes were precipitated by addition of protein A/G Plus Agarose beads 
for 2 hours at 4 °C. Following brief centrifugation, immunocomplexes were washed 
five times with 1 ml of lysis buffer, and finally resuspended in 100 µl of SDS sample 
buffer 2X. Protein complexes were then analysed by Western blotting.  
Immunoprecipitates were subjected to sodium dodecyl sulphate–polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) for 
immunoblotting. After blocking with blocking buffer (Odyssey® Blocking Buffer LI-
COR), the corresponding PVDF membranes were incubated with anti-NOX1 goat 
polyclonal antibody (Sigma-Aldrich) with anti-NOXA1 mouse polyclonal antibody 
(Abcam) or anti-NOX2 goat polyclonal with anti-p47phox mouse monoclonal antibody 
(Santa Cruz, USA) overnight at 4 °C. The PVDF membranes were washed three times 
with wash buffer (150 mM NaCl, 10 mM Tris–HCl, pH 7.0, and 0.05 % Tween 20) and 
then incubated with secondary antibodies (1:15,000) for 1 hour, washed with wash 
buffer, and imaged on the Odyssey Clx. Secondary antibodies were produced in goat 
and mouse to the species of the primary antibody and were conjugated with IRdye 
fluorophores visible in the 700 and 800 channels of the CLx imager. Images were 
acquired on the CLx imager at 169 µm resolution and all processed images were free 
of pixel saturation. 
 
Statistical analysis 
CMH oxidation rate = 
[CM●]   x   Volume 
Platelet density x Volume x Time 
We utilised the statistical software Graphpad Prism 7 for Windows (version 7.03, 
February 20th 2017). For dual comparisons we utilised t-test, while for multiple 
comparisons we used either Analysis Of Variance (ANOVA) plus multiple comparison 
post-tests (such as Bonferroni’s or Tukey’s test) or Non Parametric Tests such as 
Kruskal-Wallis. The decision on whether using ANOVA or non-parametric tests was 
based on the analysis of data normality (Kolmogorov-Smirnov’s test) and 
homoscedasticity (Bartlett’s test). Results were expressed as the mean + standard 
error (SEM) throughout the manuscript. Differences were considered significant at p < 
0.05. 
 
 













